CPT® Code 91313

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

The CPT® Code 91313 refers to a specific vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as coronavirus disease (COVID-19). This vaccine utilizes a bivalent formulation, meaning it contains messenger RNA (mRNA) components that correspond to both the original strain of the virus and a variant strain associated with the omicron variant, specifically targeting the BA.4 and BA.5 subvariant lineages. The vaccine is preservative-free and is administered in a dosage of 50 mcg per 0.5 mL via intramuscular injection. The mechanism of action involves the use of lipid nanoparticles (LNP) to encapsulate the mRNA, allowing it to be delivered effectively into the body's cells. Once inside, the cells utilize the mRNA as a template to produce the spike protein found on the surface of the coronavirus. This process triggers an immune response, prompting the body to generate antibodies that can recognize and combat the virus if the individual is exposed in the future. The vaccine is intended for individuals aged 18 years and older who have previously received COVID-19 vaccinations, serving as a booster to enhance their immune protection. It is important to note that while this code reports the supply of the vaccine, the actual administration of the vaccine is documented separately using the appropriate administration code.